ERYTHROMYCIN
LOE ApproachingNDATOPICALSOLUTION
Approved
Jun 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
14
Data completeness
4/8 — Partial
ERYTHROMYCIN by Eli Lilly and Company is clinical pharmacology orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Approved for the following infections caused by chlamydia trachomatis conjunctivitis of the newborn, pneumonia of infancy, urogenital infections during pregnancy and 8 more indications. First approved in 1980.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Erythromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is approved for treating infections caused by Chlamydia trachomatis, Streptococcus species, Haemophilus influenzae, and other gram-positive and gram-negative organisms, with particular utility in penicillin-allergic patients and neonatal conjunctivitis.
LOE Approaching
Product approaching loss of exclusivity with modest competitive pressure (30/100), suggesting team consolidation and focus on generic optimization rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Orally administered erythromycin ethylsuccinate suspension is readily and reliably absorbed under both fasting and nonfasting conditions. Erythromycin diffuses readily into most body fluids. Only low concentrations are normally achieved in the spinal fluid, but passage of the…
Worked on ERYTHROMYCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.